Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWL4MI)

• Drug Name: SSR-69071 Drug Info
• Synonyms: SSR 69071; 344930-95-6; SSR69071; DSSTox_RID_82301; DSSTox_CID_27368; DSSTox_GSID_47368; MLS006010264; SCHEMBL4295477; CHEMBL1354892; DTXSID1047368; CTK8E8740; CHEBI:93283; MolPort-023-276-460; HMS3269M07; ZINC1490807; Tox21_300247; AKOS024457139; NCGC00254231-01; NCGC00167751-02; NCGC00167751-01; NCGC00167751-03; SMR001822512; RT-015782; LS-191133; FT-0724044; CAS-344930-95-6; J-019626; BRD-K72895815-001-01-4

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 9872438
  ChEBI ID: CHEBI:93283
  CAS Number: CAS 344930-95-6
  TTD Drug ID: DMWL4MI

Molecule-Related Drug Atlas

Drug(s) Targeting Pancreatic elastase 1 (CELA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha 1-PI	DMXC1K9	Alpha-1 antitrypsin deficiency	5C5A	Approved	[4]
Erdosteine	DM6QFSV	Bronchitis	CA20	Approved	[5]
Sivelestat	DM6BZCV	Crohn disease	DD70	Phase 3	[6]
Mdl 101,146	DMRSOBG	Inflammation	1A00-CA43.1	Terminated	[7]
WIN-63759	DMRV48P	Emphysema	CA21	Terminated	[8]
SYN-1134	DMG2SQM	Cystic fibrosis	CA25	Terminated	[9]
PBI-1101	DMWD1RC	Inflammation	1A00-CA43.1	Terminated	[10]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[7]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[11]
Dimethylformamide	DML6O4N	Discovery agent	N.A.	Investigative	[12]

Drug(s) Affected By Thyroxine 5-deiodinase (DIO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[14]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[15]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[13]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[3]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[13]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[17]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[13]

Drug(s) Affected By Type II iodothyronine deiodinase (DIO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[18]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[19]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[16]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[23]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[3]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[24]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pancreatic elastase 1 (CELA1)	TT3NKIB	CELA1_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Thyroxine 5-deiodinase (DIO3)	OTNTITOT	IOD3_HUMAN	Gene/Protein Processing	[3]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014569)
• [2] Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901.
• [3] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [4] Elastase inhibitors. J Soc Biol. 2001;195(2):143-50.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8.
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995.
• [9] EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans.
• [10] CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage.
• [11] Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
• [12] Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6.
• [13] Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006 Dec;147(12):5845-54. doi: 10.1210/en.2006-0590. Epub 2006 Aug 24.
• [14] MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocr Relat Cancer. 2016 Mar;23(3):135-46. doi: 10.1530/ERC-15-0162.
• [15] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [16] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [17] Disturbance of the Dlk1-Dio3 imprinted domain may underlie placental Dio3 suppression and extracellular thyroid hormone disturbance in placenta-derived JEG-3 cells following decabromodiphenyl ether (BDE209) exposure. Toxicology. 2021 Jun 30;458:152837. doi: 10.1016/j.tox.2021.152837. Epub 2021 Jun 21.
• [18] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [19] The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes. 2007 Mar;56(3):767-76. doi: 10.2337/db06-1488.
• [20] Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology. 2009 Apr;150(4):1976-83. doi: 10.1210/en.2008-0938. Epub 2008 Nov 26.
• [21] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [22] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [23] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [24] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [25] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.